NCT06521567 - A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 6, 2025

Primary Completion Date

January 2, 2032

Study Completion Date

January 2, 2032

Conditions

MelanomaHodgkin LymphomaHigh and Low Grade GliomaGlioblastoma Multiforme (GBM)Diffuse Intrinsic Pontine Glioma (DIPG)EpendymomaOsteosarcomaHepatic TumorsHepatoblastomaHepatocellular Carcinoma (HCC)Fibrolamellar CarcinomaRhabdomyosarcoma

Interventions

DRUG

Cobolimab

Cobolimab will be administered

DRUG

Dostarlimab

Dostarlimab will be administered

Trial Locations (18)

2100

GSK Investigational Site, Copenhagen

15006

GSK Investigational Site, Phaha 5

28009

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

33076

GSK Investigational Site, Bordeaux

40138

GSK Investigational Site, Bologna

45229

GSK Investigational Site, Cincinnati

46026

GSK Investigational Site, Valencia

52242

GSK Investigational Site, Iowa City

53792

GSK Investigational Site, Madison

61300

GSK Investigational Site, Brno

67098

GSK Investigational Site, Strasbourg

75248

GSK Investigational Site, Paris

80123

GSK Investigational Site, Napoli

90048

GSK Investigational Site, Los Angeles

07601

GSK Investigational Site, Hackensack

02903

GSK Investigational Site, Providence

08035

GSK Investigational Site, Barcelona